Cbt protein, Drosophila

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null